GlassScriptPhysician profile
Kew Jung Lee
NPI 1669463618
$2,113.89
in general payments reported to CMS, 2019-2025
25 companies · $37.32 in 2025
The $37.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $148 · 2022: $23.47 · 2024: $71.93 · 2025: $37.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $281.33 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $269.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $237.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $210.17 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $197.29 | 2019-2020 | |
| Allergan, INC. | $135.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $91.54 | 2019 | |
| Lilly USA, LLC | $80.66 | 2019-2025 | Zepbound |
| Gilead Sciences, INC. | $63.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.21 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $46.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.74 | 2019 | |
| Amgen INC. | $31.85 | 2019 | |
| Phadia US INC. | $29.33 | 2019-2025 | Immunocap |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.77 | 2019 | |
| Dermira, INC. | $26.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.69 | 2019 | |
| Astellas Pharma US INC | $23.80 | 2019 | |
| Penumbra, INC. | $23.47 | 2022 | |
| Adlon Therapeutics L.P. | $19.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.05 | 2019 | |
| Abbvie INC. | $17.96 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kew Jung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.